A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2006
08/24/2006	WO2006086921A1 A process for the preparation of clopidogrel
08/24/2006	WO2006086888A1 Compositions for treatment of diseases of the nail unit
08/24/2006	WO2006086871A1 Medium-chain length fatty alcohols as stimulators of hematopoiesis
08/24/2006	WO2006086865A2 Combi-preparation of nucleoside and non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infections
08/24/2006	WO2006086862A1 Use of aromatic flavouring agents with high melting point as solubilizing agents
08/24/2006	WO2006086856A1 Combination therapeutic compositions and method of use
08/24/2006	WO2006086838A1 Flavivirus replicon constructs for tumour therapy
08/24/2006	WO2006086837A1 Non-surgical mulesing
08/24/2006	WO2006086821A1 ANTISENS MODULATION OF INTEGRIN α4 EXPRESSION
08/24/2006	WO2006078891A3 Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives
08/24/2006	WO2006076598A3 Bicyclic heterocycles as cannabinoid receptor modulators
08/24/2006	WO2006076387A3 Cyanidin-3-glucoside as an anti-neoplastic agent
08/24/2006	WO2006075925A3 Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide
08/24/2006	WO2006071644A8 Selective inhibitors of erk protein kinases and uses therof
08/24/2006	WO2006070195A8 Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
08/24/2006	WO2006067635A3 USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
08/24/2006	WO2006067599A3 Stable oral benzimidazole compositions and process of preparation thereof
08/24/2006	WO2006066006A3 Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
08/24/2006	WO2006065853A3 Crystalline forms of a factor xa inhibitor
08/24/2006	WO2006065722A3 Compositions and methods for pulmonary conditions
08/24/2006	WO2006065686A3 Spiro derivatives as lipoxygenase inhibitors
08/24/2006	WO2006063829A3 Methamphetamine derivatives and conjugates for immunoassay
08/24/2006	WO2006063178A3 Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (vr1) and uses thereof
08/24/2006	WO2006063048A3 Ibudilast for treating neuropathic pain and associated syndromes
08/24/2006	WO2006062972A3 Heterocyclic compounds as inhibitors of factor viia
08/24/2006	WO2006062655A3 Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4] triazol-1-yl}-1h-pyrrolo[2,3-c]pyridin-3-yl}-ethane-1,2-dione
08/24/2006	WO2006061340A3 Stable, hormone-containing (intermediate) product
08/24/2006	WO2006061156A3 Medicament for hygienic application inside the ear
08/24/2006	WO2006060419A3 Biomarkers for pre-selection of patients for anti-igf1r therapy
08/24/2006	WO2006056850A3 Chroman compounds
08/24/2006	WO2006056823A8 Modulating retinal pigmented epithelium permeation by inhibiting or activating vegfr-1
08/24/2006	WO2006055940A3 Block copolymers of polycaprolactone and poly (propylene fumarate)
08/24/2006	WO2006055833A3 Gtpase inhibitors and use thereof for controlling platelet hyperactivity
08/24/2006	WO2006053323A3 Inhibitors of hiv-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof
08/24/2006	WO2006053043A3 Methods of treating diabetes mellitus
08/24/2006	WO2006053014A3 Selective inhibition of rock1 in cardiac therapy
08/24/2006	WO2006047661A3 Phosphonate derivatives of mycophenolic acid
08/24/2006	WO2006047579A3 Vitamin e tpgs fluid concentrate comprising a low percentage of water
08/24/2006	WO2006046096A3 A polymorphic form of narwedine and its use in the synthesis of galantamine
08/24/2006	WO2006044821A8 Crf receptor antagonists and methods relating thereto
08/24/2006	WO2006043858A3 Method for cleaning the internal environment of an organism and endoecological correction agent
08/24/2006	WO2006041843A3 Pharmaceutical dosage form comprising meloxicam
08/24/2006	WO2006040149A9 Heterocyclic ketone compounds for treating alzheimer’s disease
08/24/2006	WO2006039545A3 Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
08/24/2006	WO2006035067A3 Hiv inhibiting 5-heterocyclyl pyrimidines
08/24/2006	WO2006034491A3 Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
08/24/2006	WO2006034113A3 Quinolone analogs as cell proliferation inhibitors
08/24/2006	WO2006032885A3 2-substituted estrogen sulphamates for inhibition of steroid sulphatase
08/24/2006	WO2006029074A3 Methods for transmembrane treatment and prevention of otitis media
08/24/2006	WO2006026313A3 Cancer treatment method
08/24/2006	WO2006025991A3 Isoindoline compounds and methods of making and using the same
08/24/2006	WO2006025924A3 Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
08/24/2006	WO2006024944A3 Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
08/24/2006	WO2006020561A3 Antibacterial agents
08/24/2006	WO2006019955A3 Antiviral methods and compositions
08/24/2006	WO2006018723A3 Androgen modulators
08/24/2006	WO2006017822A3 Quinazoline derivatives and their use in the treatment of thrombocythemia
08/24/2006	WO2006015154A3 Compositions and methods for nutrition supplementation
08/24/2006	WO2006014877A3 Potassium channel inhibitors
08/24/2006	WO2006011136A3 Novel naphthoquinone derivatives and uses thereof
08/24/2006	WO2006010162A3 COMPOSITIONS COMPRISING 5-ALPHA REDUCTASE INHIBITORS, AND SERMs AND METHODS OF USE THEREOF
08/24/2006	WO2006009464A3 Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities
08/24/2006	WO2006007528A3 Lxr/rxr-related methods and compositions
08/24/2006	WO2006007375A3 Use of bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes
08/24/2006	WO2006005142A3 Mono- and polycyclic compounds with therapeutic activity, pharmaceutical compositions including them and intermediates for making them
08/24/2006	WO2006005063A3 Methods and compositions
08/24/2006	WO2006001958A3 Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
08/24/2006	WO2005123096A3 Compositions and methods of use of dimer digallates
08/24/2006	WO2005116002B1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
08/24/2006	WO2005110484A3 Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration
08/24/2006	WO2005110387A3 Systems and methods for administering a medical regimen
08/24/2006	WO2005107726A3 Method for the treatment of back pain
08/24/2006	WO2005102303A3 Antiprostaglandins for the treatment of ocular pathologies
08/24/2006	WO2005097114A3 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
08/24/2006	WO2005082413A3 Ciclesonide and glycopyrronium combination
08/24/2006	WO2005074460A9 Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
08/24/2006	WO2005070042A8 Novel chemical compounds
08/24/2006	WO2005030134A3 Relationship of a specific metabolite to insulin resistance
08/24/2006	WO2005004810A3 Arylsulfonamide derivatives
08/24/2006	WO2005001031A3 Modulation of the rna interference pathway
08/24/2006	WO2004094374A3 Preparation of (s)-clopidogrel and related compounds
08/24/2006	WO2003070193A3 RNA interference mediated inhibition of HIV gene expression using short interfering nucleic acid (siNA)
08/24/2006	WO2003043627A8 New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma
08/24/2006	US20060191028 Developmental animal model of temporal lobe epilepsy
08/24/2006	US20060189816 Product
08/24/2006	US20060189812 Regioselective halogenation of nicotine and substituted nicotines
08/24/2006	US20060189810 Novel sulfonamide inhibitors of aspartyl protease
08/24/2006	US20060189809 Method for the synthesis of quinoline derivatives
08/24/2006	US20060189808 Heterocyclic inhibitors of MEK and methods of use thereof
08/24/2006	US20060189805 Characterized by the formation and isolation of intermediate compounds in salified form; by using the intermediate of the present process in the subsequent reductive passage, it is possible to obtain emtricitabine in a purity that allows its direct crystallization; viricides
08/24/2006	US20060189800 Indolopyrrolocabazole derivative and antitumor agent
08/24/2006	US20060189785 Using biocompatible, low molecular weighty, water solubler polymer; injectable
08/24/2006	US20060189701 Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections
08/24/2006	US20060189700 Pharmaceutical compositions
08/24/2006	US20060189699 Antimicrobial trinervitane derivatives
08/24/2006	US20060189698 Treatment of interstitial cystitis
08/24/2006	US20060189697 Crystalline ACAT inhibitor
08/24/2006	US20060189696 Polyamine conjugates with acidic retinoids and preparation thereof
08/24/2006	US20060189695 External preparation for improving coital function
08/24/2006	US20060189694 Composition and method for treating neurological disease

1 ... 4118 4119 4120 4121 4122 4123 4124 4125 4126 4127 4128 4129 4130 4131 4132 4133 4134 4135 4136 4137 4138 ... 7860